• Alaunos Therapeutics adopted second amended and restated bylaws, effective Sept. 16, 2026.
• Stockholder meeting quorum cut to 33.33% of voting power from a majority of outstanding voting shares.
• Board and committee quorum remains a majority.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-393462), on September 17, 2026, and is solely responsible for the information contained therein.